Enforced expression or amplification of MAP3K8 promotes BRAFi and MEKi resistance in melanoma cells, and MAP3K8 upregulation is observed in a group of disease-progressed melanoma patients on BRAFi or MEKi treatment 166. Here, MAP3K8 is linked to melanoma.